# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Edward Tenthoff reiterates Century Therapeutics (NASDAQ:IPSC) with a Overweight and lowers the price t...
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including syste...
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond ...
Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived...
Canaccord Genuity analyst Bill Maughan maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and raises the price target f...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Century Therapeutics (NASDAQ:IPSC) with a Buy and maintains $13 p...
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(2.30) per share which missed the analyst consensus estimate o...